Unum Therapeutics

General Information

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Our proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. Our product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development.

Employees: 53
Founded: 2014
Contact Information
Address 200 Cambridge Park Drive, Suite 3100, Cambridge, MA 02140, US
Phone Number (617) 945-5576
Web Address http://www.unumrx.com
View Prospectus: Unum Therapeutics
Financial Information
Market Cap $355.4mil
Revenues $8.4 mil (last 12 months)
Net Income $-25.6 mil (last 12 months)
IPO Profile
Symbol UMRX
Exchange NASDAQ
Shares (millions): 5.8
Price range $12.00 - $12.00
Est. $ Volume $69.2 mil
Manager / Joint Managers Morgan Stanley/ Cowen
CO-Managers SunTrust Robinson Humphrey/ Wedbush Securities
Expected To Trade: 3/29/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change